Form 8-K - Current report:
SEC Accession No. 0001193125-19-044774
Filing Date
2019-02-20
Accepted
2019-02-20 08:15:32
Documents
1
Period of Report
2019-02-19
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d705652d8k.htm 8-K 14617
  Complete submission text file 0001193125-19-044774.txt   15669
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 19617139
SIC: 2836 Biological Products, (No Diagnostic Substances)